Skip to main content

Table 2 Outcome measures at baseline and at the final assessment.

From: A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study

 

Baseline (V1)

Final (V10)

CGI

  

   Risperidone

4.40 (± 0.60)

2.84 (± 1.02)

   Paroxetine

3.81 (± 1.33)

2.67 (± 0.71)

   Statistics3

χ2 = 7.10, df = 5, n.s

 

PDSS

  

   Risperidone

13.5 (± 4.42)

7.87 (± 5.87)

   Paroxetine

12.38 (± 6.77)

8.35 (± 6.15)

   Statistics3

t = 0.715, df = 49, n.s.

 

PDSS question 1 1

  

   Risperidone

1.16 (± 0.058)

0.70 (± 0.088)

   Paroxetine

0.94 (± 0.072)

0.60 (± 0.11)

   Statistics3

t = 1.77, df = 29.47, p = n.s.

 

PDSS question 2 2

  

   Risperidone

2.41 (± 0.875)

1.28 (± 1.17)

   Paroxetine

2.39 (± 1.27)

1.52 (± 1.12)

   Statistics3

t = 0.049, df = 36.55, n.s.

 

Ham-A

  

   Risperidone

25.09 (± 5.27)

13.75 (± 9.67)

   Paroxetine

27.76 (± 7.75)

16.22 (± 9.51)

   Statistics3

t = 1.49, df = 51, n.s.

 

SPAS-p

  

   Risperidone

72.53 (± 27.51)

74.69 (± 24.6)

   Paroxetine

87.52 (± 25.46)

84.61 (± 30.12)

   Statistics3

t = 2.00, df = 51, p = 0.051

 

Ham-D

  

   Risperidone

26.19 (± 8.37)

17.52 (± 10.91)

   Paroxetine

31.0 (± 8.74)

21.68 (± 11.79)

   Statistics3

t = 2.01, df = 51, p = 0.049

 
  1. Initial and final assessments for all outcome measures.
  2. 1 – panic attack frequency
  3. 2 – panic attack severity
  4. 3 – testing the difference in baseline scores between treatment groups
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us